39 citations
,
June 2019 in “Frontiers in Endocrinology” This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.
8 citations
,
June 2022 in “Cancers” In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.
1 citations
,
January 2024 in “Pharmaceuticals” The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.
January 2023 in “Cutaneous and Ocular Toxicology” This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.
37 citations
,
January 2016 in “Drug design, development and therapy” This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.
January 2025 in “Journal of Crohn s and Colitis” In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.
January 2023 in “Discovery medicine” This study found that Cepharanthine may mitigate doxorubicin-induced senescence by reducing SA-β-Gal activity and restoring autophagy in cell models, offering insights for antiaging drug development.
June 2024 in “Journal of Clinical Oncology” This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.
34 citations
,
January 2023 in “Therapeutic Advances in Medical Oncology” This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.
This observational study reviewed thyroid eye disease patients treated with teprotumumab at one center, reporting common side effects like fatigue and dry eye symptoms, with serious adverse events including two cases of blood clots and one pulmonary embolism.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its inhibitory effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for preventing skin tumor promotion compared to individual treatments.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.
2 citations
,
May 2011 in “Journal of Clinical Oncology” This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.
March 2022 in “International Journal of Trichology” In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.
3 citations
,
October 2025 in “Cancer” This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for inhibiting skin tumor promotion compared to individual treatments.
March 2024 in “Faculty of 1000 Research Ltd” In this study, researchers at Jawaharlal Nehru Medical College are comparing the effectiveness and side effects of Adapalene gel (0.1%) and Tazarotene gel (0.05%) in acne treatment among patients aged 12-35, with assessments every 4, 8, and 12 weeks. Results are not reported yet.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
5 citations
,
March 2021 in “Hepatitis Monthly” This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.
July 2025 in “The Journal of Dermatology” This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.
January 2021 in “Journal of Cancer Therapy” This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.
1 citations
,
April 2023 in “Heliyon” In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.
44 citations
,
May 2023 in “MedComm” This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
April 2026 in “Preprints.org” This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.